What is Digital Health Acquisition's operating income?

Digital Health Acquisition's total operating income in 2025 was -$9.58 million, based on the following breakdown: Total Gross Profit: $7.36 million Total Operating Expenses: $16.94 million

Digital Health Acquisition (DHAC) Financials

$0.10 0.00 (-3.48%)

As of 07/17/2026

Compare

Annual Income Statements for Digital Health Acquisition

This table shows Digital Health Acquisition's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-3.24	-3.76	-58	-15
Consolidated Net Income / (Loss)	-3.24	-3.73	-58	-15
Net Income / (Loss) Continuing Operations	-3.24	-3.64	-58	-15
Total Pre-Tax Income	-3.06	-1.89	-59	-15
Total Operating Income	-3.59	-1.87	-62	-9.58
Total Gross Profit	0.00	3.83	7.18	7.36
Total Revenue	0.00	5.77	10	15
Operating Revenue	-	5.77	10	15
Total Cost of Revenue	0.00	1.93	3.24	7.26
Operating Cost of Revenue	-	1.93	3.24	7.26
Total Operating Expenses	3.59	5.71	69	17
Selling, General & Admin Expense	3.59	1.20	6.55	10
Other Operating Expenses / (Income)	-	4.42	5.31	6.90
Impairment Charge	-	0.00	57	0.00
Restructuring Charge	-	0.09	0.79	0.00
Total Other Income / (Expense), net	0.54	0.08	2.81	-5.06
Interest Expense	0.13	0.19	0.86	3.03
Other Income / (Expense), net	-0.26	0.27	3.66	-2.03
Income Tax Expense	0.19	1.84	-1.64	0.07
Basic Earnings per Share	($0.25)	($0.38)	($5.65)	($0.73)
Weighted Average Basic Shares Outstanding	12.74M	10.00M	10.21M	20.14M
Diluted Earnings per Share	($0.25)	($0.38)	($5.65)	($0.73)
Weighted Average Diluted Shares Outstanding	12.74M	10.00M	10.21M	20.14M
Weighted Average Basic & Diluted Shares Outstanding	-	-	-	47.30M

This table shows Digital Health Acquisition's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-0.11	-1.33	0.06	-0.63	-54	-3.21	-3.96	-2.61	-0.29	-7.85	-2.60
Consolidated Net Income / (Loss)	-0.10	-1.30	0.09	-0.67	-54	-3.21	-3.96	-2.61	-0.29	-7.85	-2.60
Net Income / (Loss) Continuing Operations	-0.10	-1.21	0.09	-0.67	-54	-3.21	-3.96	-2.61	-0.29	-7.85	-2.60
Total Pre-Tax Income	-0.33	0.94	0.09	-2.34	-54	-3.18	-3.95	-2.61	-0.29	-7.80	-2.58
Total Operating Income	-0.27	-0.28	0.10	-0.93	-58	-3.03	-1.83	-2.25	-2.06	-3.44	-2.97
Total Gross Profit	0.97	2.04	1.23	0.78	2.78	2.38	1.86	1.59	2.07	1.83	1.20
Total Revenue	1.45	3.02	1.62	1.71	3.35	3.73	3.32	3.39	3.98	3.93	3.16
Operating Revenue	1.45	-	1.62	1.71	3.35	3.73	3.32	3.39	3.98	3.93	3.16
Total Cost of Revenue	0.48	0.98	0.39	0.93	0.57	1.35	1.46	1.80	1.91	2.09	1.96
Operating Cost of Revenue	0.48	-	0.39	0.93	0.57	1.35	1.46	1.80	1.91	2.09	1.96
Total Operating Expenses	1.25	2.32	1.13	1.71	61	5.41	3.69	3.84	4.13	5.27	4.17
Selling, General & Admin Expense	0.22	-0.06	0.21	0.57	2.22	3.56	2.03	2.17	2.92	2.92	2.44
Other Operating Expenses / (Income)	1.01	-	0.89	0.91	1.73	1.77	1.66	1.67	1.21	2.36	1.73
Total Other Income / (Expense), net	-0.06	1.31	-0.01	-1.41	4.38	-0.15	-2.11	-0.35	1.77	-4.36	0.40
Interest Expense	0.04	-0.06	0.01	0.34	0.76	-0.26	0.73	0.37	0.76	1.18	0.11
Other Income / (Expense), net	-0.02	1.33	0.00	-1.07	5.14	-0.41	-1.38	0.01	2.52	-3.18	0.51
Income Tax Expense	-0.23	-	0.00	-1.68	0.01	0.03	0.01	0.00	0.00	0.05	0.02
Basic Earnings per Share	($0.01)	$0.17	$0.01	($0.12)	($3.58)	($1.96)	($0.24)	($0.16)	($0.02)	($0.31)	($0.05)
Weighted Average Basic Shares Outstanding	10.00M	10.00M	4.64M	5.30M	15.08M	10.21M	16.31M	16.42M	16.55M	20.14M	47.90M
Diluted Earnings per Share	($0.01)	$0.17	$0.01	($0.12)	($3.58)	($1.96)	($0.24)	($0.16)	($0.02)	($0.31)	($0.05)
Weighted Average Diluted Shares Outstanding	10.00M	10.00M	4.64M	5.30M	15.08M	10.21M	16.31M	16.42M	16.55M	20.14M	47.90M
Weighted Average Basic & Diluted Shares Outstanding	3.58M	0.00	3.60M	15.27M	15.67M	0.00	-	-	31.35M	47.30M	48.60M

This table details how cash moves in and out of Digital Health Acquisition's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-0.65	-0.11	0.21	4.94
Net Cash From Operating Activities	-1.39	-0.63	-5.79	-3.45
Net Cash From Continuing Operating Activities	-1.39	-0.63	-5.79	-3.45
Net Income / (Loss) Continuing Operations	-3.24	-3.73	-58	-15
Consolidated Net Income / (Loss)	-3.24	-3.73	-58	-15
Depreciation Expense	-	0.00	1.32	2.59
Amortization Expense	-	0.09	0.06	0.07
Non-Cash Adjustments To Reconcile Net Income	-0.67	0.03	55	4.59
Changes in Operating Assets and Liabilities, net	2.52	2.97	-4.68	4.02
Net Cash From Investing Activities	110	-0.00	-0.03	-0.03
Net Cash From Continuing Investing Activities	110	-0.00	-0.03	-0.03
Purchase of Property, Plant & Equipment	-	-0.00	-0.06	-0.03
Divestitures	-	0.00	0.03	0.00
Net Cash From Financing Activities	-109	0.53	6.02	8.42
Net Cash From Continuing Financing Activities	-109	0.53	6.02	8.42
Repayment of Debt	-0.06	0.00	-0.52	1.61
Repurchase of Common Equity	-110	-	-0.01	-0.00
Payment of Dividends	-	0.00	0.00	-0.01
Issuance of Debt	1.15	0.39	5.46	0.00
Issuance of Common Equity	-	-	0.00	7.02
Other Financing Activities, net	0.00	0.00	1.09	-0.20
Cash Interest Paid	-	0.00	0.11	0.21

This table details how cash moves in and out of Digital Health Acquisition's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	0.09	-0.04	0.57	0.42	1.22	-2.00	0.10	-0.14	0.18	4.79	-3.92
Net Cash From Operating Activities	-0.05	-0.11	0.58	-3.17	-0.22	-2.97	-0.44	-0.32	-0.75	-1.93	-2.45
Net Cash From Continuing Operating Activities	-0.05	-0.11	0.58	-3.17	-0.22	-2.97	-0.42	-0.34	-0.75	-1.93	-2.45
Net Income / (Loss) Continuing Operations	-0.10	-2.74	0.09	-0.67	-54	-3.21	-3.96	-2.61	-0.29	-7.85	-2.60
Consolidated Net Income / (Loss)	-0.10	-2.74	0.09	-0.67	-54	-3.21	-3.96	-2.61	-0.29	-7.85	-2.60
Depreciation Expense	0.00	0.00	0.00	0.00	0.65	0.67	0.65	0.65	0.65	0.65	0.65
Amortization Expense	0.02	0.00	0.01	0.00	0.01	0.04	0.02	0.02	0.02	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	0.14	-0.16	0.01	1.65	53	0.82	1.91	0.74	-2.30	4.20	0.29
Changes in Operating Assets and Liabilities, net	-0.11	2.79	0.47	-4.16	0.32	-1.30	0.96	0.86	1.17	1.07	-0.78
Net Cash From Investing Activities	-	-0.00	-0.01	-0.01	-0.00	-0.00	-0.01	-0.00	-0.01	-0.01	-0.13
Net Cash From Continuing Investing Activities	-	-0.00	-0.01	-0.01	-0.00	-0.00	-0.01	-0.00	-0.01	-0.01	-0.13
Purchase of Property, Plant & Equipment	-	-0.00	-0.01	-0.04	-0.00	-0.00	-0.01	-0.00	-0.01	-0.01	-0.03
Purchase of Investments	-	-	-	-	-	-	0.00	-	-	-	-0.10
Net Cash From Financing Activities	0.14	0.07	0.00	3.60	1.45	0.98	0.54	0.21	0.94	6.73	-1.34
Net Cash From Continuing Financing Activities	0.14	0.07	0.00	3.60	1.45	0.98	0.54	0.21	0.94	6.73	-1.34
Repayment of Debt	-	-	0.00	-0.41	-0.04	-0.07	0.00	-0.00	-0.64	2.28	-0.88
Repurchase of Common Equity	-	-	-	-	-	-0.01	0.00	-	-	-	-0.05
Payment of Dividends	-	-	0.00	-	-	-	-0.01	-	-	-	0.00
Issuance of Debt	-	0.07	0.00	2.70	2.00	0.76	0.51	0.22	1.18	-1.91	0.18
Issuance of Common Equity	-	-	0.00	-	-	-	0.09	-	0.45	6.48	0.00
Other Financing Activities, net	-	-	0.00	1.31	-0.52	0.30	-0.05	-0.01	-0.05	-0.12	-0.59
Cash Interest Paid	-	-	0.00	-	0.01	0.10	0.11	0.03	0.15	-0.07	0.21

This table presents Digital Health Acquisition's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	118	7.63	0.81	20	22
Total Current Assets	1.22	0.11	0.80	3.02	8.37
Cash & Equivalents	0.76	0.11	0.12	0.33	5.27
Accounts Receivable	-	-	0.60	2.25	2.83
Prepaid Expenses	0.46	-	0.08	0.45	0.27
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.68	0.33
Total Noncurrent Assets	117	7.53	0.00	16	14
Long-Term Investments	-	-	-	-	0.00
Goodwill	-	-	0.00	4.92	4.92
Intangible Assets	-	-	0.00	11	8.79
Other Noncurrent Operating Assets	117	7.53	0.00	0.38	0.01
Total Liabilities & Shareholders' Equity	118	7.63	0.81	20	22
Total Liabilities	4.55	7.67	5.11	20	17
Total Current Liabilities	0.18	3.30	5.11	19	16
Short-Term Debt	0.00	0.00	0.92	7.85	1.64
Accounts Payable	0.14	1.89	2.59	9.34	12
Current Deferred Revenue	-	-	0.90	0.42	1.32
Other Current Liabilities	0.04	1.22	0.69	1.33	1.72
Total Noncurrent Liabilities	4.37	4.37	0.00	1.07	0.73
Long-Term Debt	-	-	0.00	0.59	0.59
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	0.00	0.07	0.12
Other Noncurrent Operating Liabilities	4.37	4.37	0.00	0.34	0.02
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-3.33	-7.43	-4.30	-0.02	5.45
Total Preferred & Common Equity	-3.33	-7.43	-3.97	-0.02	5.45
Preferred Stock	-	-	0.00	0.00	0.00
Total Common Equity	-3.33	-7.43	-3.97	-0.02	5.45
Common Stock	0.00	0.29	6.03	68	88
Retained Earnings	-3.33	-7.72	-10	-68	-82

This table presents Digital Health Acquisition's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	8.14	1.39	79	25	19	18	19	19
Total Current Assets	0.02	0.00	5.17	7.11	3.08	2.56	3.72	4.84
Cash & Equivalents	0.00	-	1.11	2.33	0.41	0.29	0.47	1.35
Accounts Receivable	-	-	3.30	3.17	2.14	1.86	2.86	2.98
Prepaid Expenses	0.02	-	0.76	1.61	0.53	0.41	0.38	0.51
Plant, Property, & Equipment, net	0.00	0.00	0.88	0.79	0.60	0.51	0.42	0.27
Total Noncurrent Assets	8.12	1.39	73	17	16	15	15	14
Long-Term Investments	-	-	-	-	-	-	-	0.75
Goodwill	-	-	60	4.92	4.92	4.92	4.92	4.92
Intangible Assets	-	-	12	12	10	9.89	9.34	8.23
Other Noncurrent Operating Assets	8.12	1.39	0.69	0.42	0.36	0.34	0.32	0.01
Total Liabilities & Shareholders' Equity	8.14	1.39	79	25	19	18	19	19
Total Liabilities	9.39	13	24	20	23	24	24	13
Total Current Liabilities	5.02	8.97	23	19	22	23	23	12
Short-Term Debt	0.88	3.45	12	8.56	9.70	9.97	7.87	1.34
Accounts Payable	2.77	3.64	6.75	8.27	9.46	9.62	12	8.53
Current Deferred Revenue	-	-	1.02	0.68	0.85	1.17	1.15	1.45
Other Current Liabilities	1.19	1.54	2.73	1.63	1.92	2.24	2.65	0.48
Total Noncurrent Liabilities	4.37	4.37	1.30	1.06	0.97	0.95	0.89	0.90
Long-Term Debt	-	-	0.59	0.59	0.59	0.59	0.59	0.78
Capital Lease Obligations	-	-	-	0.18	-	-	-	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	0.07	0.07	0.07	0.12
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-9.15	-13	55	4.76	-3.50	-5.74	-5.58	6.32
Total Preferred & Common Equity	-9.15	-13	55	4.76	-3.50	-5.74	-5.58	6.32
Preferred Stock	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-9.15	-13	55	4.76	-3.50	-5.74	-5.58	6.32
Common Stock	0.62	0.55	65	66	68	69	69	91
Retained Earnings	-9.77	-14	-9.77	-62	-72	-74	-75	-85

This table displays calculated financial ratios and metrics derived from Digital Health Acquisition's official financial filings.

Metric	2022	2023	2024	2025
Period end date	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	4,126,123.00	3,583,966.00	15,670,936.00	32,845,380.00
DEI Adjusted Shares Outstanding	4,126,123.00	3,583,966.00	15,670,936.00	32,845,380.00
DEI Earnings Per Adjusted Shares Outstanding	-0.79	-1.05	-3.68	-0.45
Growth Metrics	-	-	-	-
Revenue Growth	0.00%	0.00%	80.74%	40.27%
EBITDA Growth	0.00%	60.77%	-3,678.98%	84.31%
EBIT Growth	0.00%	58.32%	-3,543.08%	80.15%
NOPAT Growth	0.00%	47.88%	-3,217.21%	84.58%
Net Income Growth	0.00%	-14.89%	-1,448.86%	74.50%
EPS Growth	0.00%	-52.00%	-1,386.84%	87.08%
Operating Cash Flow Growth	0.00%	54.53%	-815.21%	40.48%
Free Cash Flow Firm Growth	0.00%	0.00%	-2,793.67%	98.13%
Invested Capital Growth	0.00%	-2,428.30%	331.69%	-70.11%
Revenue Q/Q Growth	0.00%	110.30%	7.31%	1.33%
EBITDA Q/Q Growth	0.00%	63.26%	-7.09%	-56.81%
EBIT Q/Q Growth	0.00%	60.97%	-8.31%	-37.78%
NOPAT Q/Q Growth	0.00%	32.93%	-4.62%	-4.49%
Net Income Q/Q Growth	0.00%	-1.88%	-3.41%	-46.10%
EPS Q/Q Growth	0.00%	43.28%	-60.51%	69.33%
Operating Cash Flow Q/Q Growth	0.00%	47.27%	-97.97%	23.32%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	-2.55%	-135.14%
Invested Capital Q/Q Growth	0.00%	-820.11%	-31.17%	0.40%
Profitability Metrics	-	-	-	-
Gross Margin	0.00%	66.47%	68.87%	50.32%
EBITDA Margin	0.00%	-26.21%	-547.93%	-61.28%
Operating Margin	0.00%	-32.49%	-596.38%	-65.55%
EBIT Margin	0.00%	-27.84%	-561.23%	-79.43%
Profit (Net Income) Margin	0.00%	-64.61%	-553.69%	-100.65%
Tax Burden Percent	106.13%	197.43%	97.23%	100.47%
Interest Burden Percent	79.32%	117.54%	101.47%	126.12%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-1,890.38%	-127.54%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-2,208.66%	-442.38%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	4,563.01%	-413.98%
Return on Equity (ROE)	-5.72%	172.05%	2,672.62%	-541.52%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-680.39%	-19.60%
Operating Return on Assets (OROA)	0.00%	-38.04%	-562.43%	-54.76%
Return on Assets (ROA)	0.00%	-88.28%	-554.87%	-69.39%
Return on Common Equity (ROCE)	0.54%	452.91%	2,471.29%	-541.52%
Return on Equity Simple (ROE_SIMPLE)	43.66%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-2.52	-1.31	-44	-6.71
NOPAT Margin	0.00%	-22.75%	-417.47%	-45.89%
Net Nonoperating Expense Percent (NNEP)	-678.54%	692.40%	318.28%	314.83%
Return On Investment Capital (ROIC_SIMPLE)	-	38.84%	-516.44%	-87.26%
Cost of Revenue to Revenue	0.00%	33.53%	31.13%	49.68%
SG&A Expenses to Revenue	0.00%	20.85%	62.89%	68.66%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	98.97%	665.25%	115.88%
Earnings before Interest and Taxes (EBIT)	-3.85	-1.61	-58	-12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3.85	-1.51	-57	-8.96
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	7.58	2.05	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	3.63	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	7.67	2.82	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	21.61	0.00	0.00
Leverage & Solvency	-	-	-	-
Debt to Equity	0.00	-0.21	-456.66	0.41
Long-Term Debt to Equity	0.00	0.00	-32.13	0.11
Financial Leverage	3.42	-0.16	-2.07	0.94
Leverage Ratio	1.11	-1.95	-4.82	7.80
Compound Leverage Factor	0.88	-2.29	-4.89	9.84
Debt to Total Capital	0.00%	-27.34%	100.22%	29.07%
Short-Term Debt to Total Capital	0.00%	-27.34%	93.17%	21.35%
Long-Term Debt to Total Capital	0.00%	0.00%	7.05%	7.73%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-23,667.39%	9.63%	0.00%	0.00%
Common Equity to Total Capital	23,767.39%	117.70%	-0.22%	70.93%
Debt to EBITDA	0.00	-0.61	-0.15	-0.25
Net Debt to EBITDA	0.00	-0.53	-0.14	0.34
Long-Term Debt to EBITDA	0.00	0.00	-0.01	-0.07
Debt to NOPAT	0.00	-0.70	-0.19	-0.33
Net Debt to NOPAT	0.00	-0.61	-0.19	0.45
Long-Term Debt to NOPAT	0.00	0.00	-0.01	-0.09
Altman Z-Score	-0.06	-18.07	-14.19	0.00
Noncontrolling Interest Sharing Ratio	109.49%	-163.25%	7.53%	0.00%
Liquidity Ratios	-	-	-	-
Current Ratio	0.03	0.16	0.16	0.52
Quick Ratio	0.03	0.14	0.14	0.50
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	2.05	-55	-1.03
Operating Cash Flow to CapEx	0.00%	-14,592.73%	-10,475.59%	-11,513.41%
Free Cash Flow to Firm to Interest Expense	0.00	10.69	-64.26	-0.34
Operating Cash Flow to Interest Expense	-11.04	-3.31	-6.75	-1.14
Operating Cash Flow Less CapEx to Interest Expense	-11.04	-3.33	-6.82	-1.15
Efficiency Ratios	-	-	-	-
Asset Turnover	0.00	1.37	1.00	0.69
Accounts Receivable Turnover	0.00	0.00	7.31	5.76
Inventory Turnover	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	30.48	28.87
Accounts Payable Turnover	0.00	0.86	0.54	0.70
Days Sales Outstanding (DSO)	0.00	0.00	49.94	63.34
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	422.23	671.20	524.73
Cash Conversion Cycle (CCC)	0.00	-422.23	-621.26	-461.39
Capital & Investment Metrics	-	-	-	-
Invested Capital	-0.14	-3.50	8.10	2.42
Invested Capital Turnover	0.00	-3.17	4.53	2.78
Increase / (Decrease) in Invested Capital	0.00	-3.36	12	-5.68
Enterprise Value (EV)	52	44	29	0.00
Market Capitalization	45	44	21	0.00
Book Value per Share	($1.80)	($1.11)	$0.00	$0.27
Tangible Book Value per Share	($1.80)	($1.11)	($1.02)	($0.41)
Total Capital	-0.03	-3.38	8.42	7.69
Total Debt	0.00	0.92	8.44	2.23
Total Long-Term Debt	0.00	0.00	0.59	0.59
Net Debt	-0.11	0.80	8.12	-3.03
Capital Expenditures (CapEx)	0.00	0.00	0.06	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-3.30	-3.50	-8.47	-12
Debt-free Net Working Capital (DFNWC)	-3.19	-3.38	-8.14	-6.24
Net Working Capital (NWC)	-3.19	-4.30	-16	-7.88
Net Nonoperating Expense (NNE)	0.73	2.41	14	8.00
Net Nonoperating Obligations (NNO)	-0.11	0.80	8.12	-3.03
Total Depreciation and Amortization (D&A)	0.00	0.09	1.39	2.65
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-60.68%	-81.24%	-78.70%
Debt-free Net Working Capital to Revenue	0.00%	-58.62%	-78.11%	-42.68%
Net Working Capital to Revenue	0.00%	-74.63%	-153.43%	-53.90%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	($0.25)	($1.08)	$0.00	($0.73)
Adjusted Weighted Average Basic Shares Outstanding	12.74M	4.10M	0.00	20.14M
Adjusted Diluted Earnings per Share	($0.25)	($1.08)	$0.00	($0.73)
Adjusted Weighted Average Diluted Shares Outstanding	12.74M	4.10M	0.00	20.14M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	47.30M
Normalized Net Operating Profit after Tax (NOPAT)	-2.52	-1.25	-3.28	-6.71
Normalized NOPAT Margin	0.00%	-21.69%	-31.45%	-45.89%
Pre Tax Income Margin	0.00%	-32.73%	-569.46%	-100.18%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	-30.58	-8.39	-68.21	-3.83
NOPAT to Interest Expense	-19.98	-6.86	-50.74	-2.21
EBIT Less CapEx to Interest Expense	-30.58	-8.41	-68.28	-3.84
NOPAT Less CapEx to Interest Expense	-19.98	-6.88	-50.80	-2.22
Payout Ratios	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	-0.07%
Augmented Payout Ratio	-3,407.01%	0.00%	-0.01%	-0.07%

This table displays calculated financial ratios and metrics derived from Digital Health Acquisition's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	4,183,123.00	3,583,966.00	3,583,966.00	3,603,966.00	15,268,436.00	15,670,936.00	15,670,936.00	15,670,936.00	32,845,380.00	32,845,380.00	32,845,380.00
DEI Adjusted Shares Outstanding	4,183,123.00	3,583,966.00	3,583,966.00	3,603,966.00	15,268,436.00	15,670,936.00	15,670,936.00	15,670,936.00	32,845,380.00	32,845,380.00	32,845,380.00
DEI Earnings Per Adjusted Shares Outstanding	-0.03	-0.37	0.02	-0.18	-3.53	-0.20	-0.25	-0.17	-0.01	-0.24	-0.08
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	32.66%	131.11%	23.48%	104.90%	98.07%	18.67%	5.13%	-4.86%
EBITDA Growth	75.44%	172.15%	106.08%	-281.87%	-18,824.39%	-359.31%	-2,381.30%	21.25%	102.16%	-119.03%	28.78%
EBIT Growth	73.79%	172.08%	105.67%	-282.83%	-17,857.80%	-427.15%	-3,189.82%	-11.96%	100.88%	-92.64%	23.38%
NOPAT Growth	75.71%	66.61%	121.01%	-52.59%	-21,147.94%	-655.46%	-1,331.91%	-141.79%	96.47%	-13.61%	-62.41%
Net Income Growth	87.99%	-5.57%	105.00%	-55.42%	-54,598.74%	-146.09%	-4,278.83%	-292.32%	99.46%	-144.70%	34.33%
EPS Growth	80.00%	241.67%	102.22%	-33.33%	-35,700.00%	-1,252.94%	-2,500.00%	-33.33%	99.44%	84.18%	79.17%
Operating Cash Flow Growth	66.62%	83.86%	270.04%	-2,268.71%	-353.00%	-2,624.74%	-176.04%	89.77%	-241.37%	35.24%	-456.69%
Free Cash Flow Firm Growth	199.46%	0.00%	-93.61%	-160.57%	-147.48%	-545.72%	-322.64%	189.05%	114.94%	123.84%	87.30%
Invested Capital Growth	-100.34%	-2,428.30%	-547.28%	10,006.07%	3,197.01%	331.69%	175.78%	-93.19%	-79.50%	-70.11%	-0.59%
Revenue Q/Q Growth	12.50%	108.35%	-46.40%	5.59%	95.99%	11.33%	-11.06%	2.07%	17.42%	-1.37%	-19.50%
EBITDA Q/Q Growth	46.98%	479.09%	-89.38%	-1,888.75%	-2,527.55%	94.81%	6.56%	38.25%	172.16%	-626.05%	69.62%
EBIT Q/Q Growth	43.42%	454.90%	-90.09%	-2,024.52%	-2,554.10%	93.53%	6.44%	30.27%	120.79%	-1,520.26%	62.79%
NOPAT Q/Q Growth	55.11%	-46.06%	137.10%	-727.30%	-6,151.32%	94.81%	39.51%	-23.12%	8.75%	-67.16%	13.52%
Net Income Q/Q Growth	77.00%	-1,222.42%	107.27%	-803.01%	-7,995.24%	94.05%	-23.42%	34.00%	88.91%	-2,609.41%	66.88%
EPS Q/Q Growth	88.89%	1,800.00%	-94.12%	-1,300.00%	-2,883.33%	45.25%	87.76%	33.33%	87.50%	-1,450.00%	83.87%
Operating Cash Flow Q/Q Growth	63.58%	-123.72%	630.68%	-647.83%	93.04%	-1,245.63%	85.19%	26.31%	-132.45%	-155.27%	-27.31%
Free Cash Flow Firm Q/Q Growth	-0.65%	-97.24%	135.01%	-1,040.46%	22.13%	74.10%	-17.39%	476.18%	-86.93%	-58.68%	-162.53%
Invested Capital Q/Q Growth	43.56%	-820.11%	-141.13%	891.04%	-82.35%	-31.17%	-21.13%	-28.94%	-46.87%	0.40%	162.27%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.04%	67.58%	76.17%	45.40%	83.02%	63.76%	56.00%	46.86%	52.08%	46.72%	37.91%
EBITDA Margin	-19.11%	34.77%	6.89%	-116.71%	-1,564.77%	-73.01%	-76.70%	-46.41%	28.52%	-152.11%	-57.41%
Operating Margin	-18.90%	-9.28%	6.42%	-54.48%	-1,737.85%	-81.07%	-55.14%	-66.51%	-51.69%	-87.61%	-94.12%
EBIT Margin	-20.39%	34.73%	6.42%	-117.01%	-1,584.54%	-92.02%	-96.80%	-66.14%	11.71%	-168.63%	-77.95%
Profit (Net Income) Margin	-6.79%	-43.11%	5.85%	-38.92%	-1,607.50%	-85.91%	-119.21%	-77.09%	-7.28%	-199.96%	-82.28%
Tax Burden Percent	29.67%	-138.25%	100.00%	28.41%	100.02%	100.84%	100.34%	100.17%	100.00%	100.65%	100.92%
Interest Burden Percent	112.27%	89.77%	91.05%	117.07%	101.43%	92.58%	122.72%	116.36%	-62.16%	117.82%	104.59%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-0.65%	0.00%	0.00%	-9.02%	-2,075.33%	-256.97%	0.00%	-18.05%	-73.64%	-170.44%	-149.56%
ROIC Less NNEP Spread (ROIC-NNEP)	21.88%	0.00%	0.00%	-9.24%	-2,408.22%	-281.38%	0.00%	-27.40%	-58.29%	-384.51%	-160.02%
Return on Net Nonoperating Assets (RNNOA)	0.16%	0.00%	0.00%	-2.16%	-5,414.88%	581.32%	0.00%	-12.36%	1,070.42%	-359.83%	-561.66%
Return on Equity (ROE)	-0.49%	172.05%	25.41%	-11.19%	-7,490.21%	324.35%	799.50%	-30.40%	996.77%	-530.28%	-711.22%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-102.46%	-456.68%	-680.39%	-934.33%	45.91%	41.39%	-19.60%	-117.31%
Operating Return on Assets (OROA)	-0.89%	47.46%	10.47%	-20.99%	-927.89%	-92.22%	-112.92%	-18.78%	7.72%	-116.26%	-58.68%
Return on Assets (ROA)	-0.30%	-58.90%	9.53%	-6.98%	-941.33%	-86.09%	-139.06%	-21.89%	-4.80%	-137.86%	-61.94%
Return on Common Equity (ROCE)	0.07%	452.91%	41.55%	-9.56%	9,381.55%	299.92%	865.84%	-30.40%	996.78%	-530.28%	-711.22%
Return on Equity Simple (ROE_SIMPLE)	39.97%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.19	-0.28	0.10	-0.65	-41	-2.12	-1.28	-1.58	-1.44	-2.41	-2.08
NOPAT Margin	-13.23%	-9.28%	6.42%	-38.14%	-1,216.49%	-56.75%	-38.59%	-46.56%	-36.18%	-61.32%	-65.88%
Net Nonoperating Expense Percent (NNEP)	-22.54%	293.47%	0.47%	0.21%	332.89%	24.41%	39.94%	9.35%	-15.35%	214.07%	10.46%
Return On Investment Capital (ROIC_SIMPLE)	-	8.31%	-1.06%	-0.96%	-289.57%	-25.16%	-18.86%	-32.68%	-49.94%	-31.32%	-24.65%
Cost of Revenue to Revenue	32.96%	32.42%	23.83%	54.60%	16.98%	36.24%	44.00%	53.14%	47.92%	53.28%	62.09%
SG&A Expenses to Revenue	15.49%	-1.86%	13.00%	33.21%	66.13%	95.24%	61.19%	64.09%	73.28%	74.25%	77.22%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	85.94%	76.85%	69.75%	99.88%	1,820.86%	144.83%	111.13%	113.37%	103.77%	134.33%	132.03%
Earnings before Interest and Taxes (EBIT)	-0.30	1.05	0.10	-2.00	-53	-3.44	-3.22	-2.24	0.47	-6.62	-2.46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.28	1.05	0.11	-2.00	-52	-2.73	-2.55	-1.57	1.14	-5.97	-1.81
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.58	4.78	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	18.17	7.58	5.72	4.04	2.34	2.05	1.55	1.32	0.69	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.65	2.53	3.63	4.49	6.27	7.47	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	21.37	7.67	6.36	5.56	3.06	2.82	2.37	2.06	1.25	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	140.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	140.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	163.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	21.61	7.75	0.00	0.00	0.00	0.00	1.74	6.14	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.70	-0.21	-0.29	0.24	1.96	-456.66	-2.94	-1.84	-1.52	0.41	0.34
Long-Term Debt to Equity	0.00	0.00	0.00	0.01	0.16	-32.13	-0.17	-0.10	-0.11	0.11	0.12
Financial Leverage	0.01	-0.16	-0.29	0.23	2.25	-2.07	-0.87	0.45	-18.36	0.94	3.51
Leverage Ratio	1.14	-1.95	-0.66	1.63	9.46	-4.82	-1.35	1.98	-53.57	7.80	13.60
Compound Leverage Factor	1.28	-1.75	-0.60	1.91	9.60	-4.46	-1.65	2.30	33.30	9.19	14.23
Debt to Total Capital	-230.65%	-27.34%	-40.52%	19.13%	66.23%	100.22%	151.45%	218.76%	293.32%	29.07%	25.15%
Short-Term Debt to Total Capital	-230.65%	-27.34%	-40.52%	18.25%	60.73%	93.17%	142.71%	206.46%	272.89%	21.35%	15.90%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.88%	5.50%	7.05%	8.74%	12.30%	20.44%	7.73%	9.25%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-2,080.90%	9.63%	-15.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	2,411.55%	117.70%	155.59%	80.87%	33.77%	-0.22%	-51.45%	-118.76%	-193.32%	70.93%	74.85%
Debt to EBITDA	-0.21	-0.61	10.28	-11.66	-0.18	-0.15	-0.17	-0.18	-1.48	-0.25	-0.26
Net Debt to EBITDA	-0.21	-0.53	10.28	-10.67	-0.13	-0.14	-0.17	-0.17	-1.40	0.34	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	-0.53	-0.01	-0.01	-0.01	-0.01	-0.10	-0.07	-0.10
Debt to NOPAT	-0.45	-0.70	-3.25	-13.39	-0.22	-0.19	-0.23	-0.23	-1.32	-0.33	-0.28
Net Debt to NOPAT	-0.45	-0.61	-3.25	-12.25	-0.17	-0.19	-0.22	-0.22	-1.24	0.45	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	-0.61	-0.02	-0.01	-0.01	-0.01	-0.09	-0.09	-0.10
Altman Z-Score	0.98	-7.19	-14.20	0.36	-9.97	-5.11	-5.77	-6.25	-5.74	0.00	0.00
Noncontrolling Interest Sharing Ratio	113.38%	-163.25%	-63.51%	14.58%	225.25%	7.53%	-8.30%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	0.16	0.00	0.23	0.37	0.16	0.14	0.11	0.16	0.52	0.41
Quick Ratio	0.00	0.14	0.00	0.19	0.29	0.14	0.12	0.09	0.14	0.50	0.37
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	112	3.08	7.23	-68	-53	-14	-16	61	7.91	3.27	-2.04
Operating Cash Flow to CapEx	0.00%	-6,635.81%	6,627.99%	-8,629.97%	-4,425.99%	-62,485.17%	-3,710.04%	-9,034.26%	-10,322.00%	-26,930.94%	-9,166.38%
Free Cash Flow to Firm to Interest Expense	3,071.32	0.00	776.59	-198.91	-69.55	0.00	-22.03	165.13	10.47	2.77	-18.08
Operating Cash Flow to Interest Expense	-1.34	0.00	62.22	-9.28	-0.29	0.00	-0.60	-0.89	-1.00	-1.63	-21.68
Operating Cash Flow Less CapEx to Interest Expense	-1.34	0.00	61.28	-9.39	-0.30	0.00	-0.62	-0.90	-1.01	-1.64	-21.92
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.04	1.37	1.63	0.18	0.59	1.00	1.17	0.28	0.66	0.69	0.75
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	7.31	0.00	5.35	4.78	5.76	5.64
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	30.48	0.00	19.87	23.78	28.87	33.51
Accounts Payable Turnover	0.45	0.86	0.80	0.61	0.52	0.54	0.66	0.63	0.65	0.70	0.86
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	49.94	0.00	68.21	76.37	63.34	64.68
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	811.37	422.23	454.64	595.04	701.72	671.20	553.57	576.20	559.13	524.73	422.89
Cash Conversion Cycle (CCC)	-811.37	-422.23	-454.64	-595.04	-701.72	-621.26	-553.57	-508.00	-482.77	-461.39	-358.20
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.38	-3.50	-8.43	67	12	8.10	6.39	4.54	2.41	2.42	6.35
Invested Capital Turnover	0.05	-3.17	-1.52	0.24	1.71	4.53	-11.88	0.39	2.04	2.78	2.27
Increase / (Decrease) in Invested Capital	-112	-3.36	-7.13	67	12	12	15	-62	-9.35	-5.68	-0.04
Enterprise Value (EV)	59	44	47	43	30	29	29	28	18	0.00	0.00
Market Capitalization	50	44	42	32	23	21	19	18	10	0.00	0.00
Book Value per Share	($2.19)	($1.11)	($3.69)	$15.21	$0.31	$0.00	($0.22)	($0.37)	($0.34)	$0.27	$0.13
Tangible Book Value per Share	($2.19)	($1.11)	($3.69)	($4.77)	($0.77)	($1.02)	($1.20)	($1.31)	($1.21)	($0.41)	($0.14)
Total Capital	-0.38	-3.38	-8.51	68	14	8.42	6.80	4.83	2.88	7.69	8.45
Total Debt	0.88	0.92	3.45	13	9.33	8.44	10	11	8.46	2.23	2.12
Total Long-Term Debt	0.00	0.00	0.00	0.59	0.78	0.59	0.59	0.59	0.59	0.59	0.78
Net Debt	0.87	0.80	3.45	12	7.01	8.12	9.88	10	7.99	-3.03	0.03
Capital Expenditures (CapEx)	0.00	0.00	0.01	0.04	0.00	0.00	0.01	0.00	0.01	0.01	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4.13	-3.50	-5.52	-6.45	-5.87	-8.47	-9.61	-11	-12	-12	-6.96
Debt-free Net Working Capital (DFNWC)	-4.13	-3.38	-5.52	-5.34	-3.54	-8.14	-9.20	-11	-12	-6.24	-5.61
Net Working Capital (NWC)	-5.00	-4.30	-8.97	-18	-12	-16	-19	-20	-20	-7.88	-6.95
Net Nonoperating Expense (NNE)	-0.09	1.02	0.01	0.01	13	1.09	2.68	1.03	-1.15	5.44	0.52
Net Nonoperating Obligations (NNO)	0.87	0.80	3.52	12	7.01	8.12	9.88	10	7.99	-3.03	0.03
Total Depreciation and Amortization (D&A)	0.02	0.00	0.01	0.01	0.66	0.71	0.67	0.67	0.67	0.65	0.65
Debt-free, Cash-free Net Working Capital to Revenue	-150.62%	-60.68%	-74.75%	-82.58%	-60.43%	-81.24%	-79.30%	-78.39%	-85.30%	-78.70%	-48.12%
Debt-free Net Working Capital to Revenue	-150.60%	-58.62%	-74.75%	-68.42%	-36.46%	-78.11%	-75.92%	-76.27%	-82.03%	-42.68%	-38.81%
Net Working Capital to Revenue	-182.52%	-74.63%	-121.41%	-226.85%	-124.59%	-153.43%	-155.94%	-148.54%	-136.58%	-53.90%	-48.10%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.02	$0.17	($0.27)	($0.06)	($3.43)	($1.96)	($0.24)	($0.16)	($0.02)	($0.31)	($0.05)
Adjusted Weighted Average Basic Shares Outstanding	4.18M	10.00M	3.60M	5.30M	15.08M	10.21M	16.31M	16.42M	16.55M	20.14M	47.90M
Adjusted Diluted Earnings per Share	$0.02	$0.17	($0.27)	($0.06)	($3.43)	($1.96)	($0.24)	($0.16)	($0.02)	($0.31)	($0.05)
Adjusted Weighted Average Diluted Shares Outstanding	4.18M	10.00M	3.60M	5.30M	15.08M	10.21M	16.31M	16.42M	16.55M	20.14M	47.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	3.58M	0.00	3.60M	15.27M	15.67M	0.00	0.00	0.00	31.35M	47.30M	48.60M
Normalized Net Operating Profit after Tax (NOPAT)	-0.19	-0.20	0.09	-0.49	-0.81	-2.06	-1.28	-1.58	-1.44	-2.41	-2.08
Normalized NOPAT Margin	-12.79%	-6.49%	5.63%	-28.80%	-24.29%	-55.20%	-38.59%	-46.56%	-36.18%	-61.32%	-65.88%
Pre Tax Income Margin	-22.89%	31.18%	5.85%	-136.98%	-1,607.24%	-85.19%	-118.80%	-76.95%	-7.28%	-198.68%	-81.53%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.15	0.00	11.18	-5.86	-69.81	0.00	-4.40	-6.11	0.62	-5.61	-21.78
NOPAT to Interest Expense	-5.29	0.00	11.18	-1.91	-53.60	0.00	-1.75	-4.30	-1.91	-2.04	-18.41
EBIT Less CapEx to Interest Expense	-8.15	0.00	10.24	-5.97	-69.82	0.00	-4.42	-6.12	0.61	-5.62	-22.02
NOPAT Less CapEx to Interest Expense	-5.29	0.00	10.24	-2.02	-53.60	0.00	-1.77	-4.31	-1.92	-2.05	-18.65
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.02%	-0.02%	-0.15%	-0.07%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.01%	-0.02%	-0.02%	-0.15%	-0.07%	-0.37%

Financials Breakdown Chart

Key Financial Trends

Digital Health Acquisition / VSee Health (NASDAQ:VSEE) shows a business that is still growing revenue, but profitability and balance-sheet strength remain major concerns. Over the last four years, revenue has generally trended upward, yet losses have persisted and in some periods widened sharply. The company also appears to be relying on external financing and has taken on meaningful liabilities relative to its asset base.

Recent quarter snapshot: Q1 2026

Revenue increased to $3.16 million in Q1 2026, up from $3.93 million in Q4 2025 and higher than many earlier quarters in 2024.
Gross profit was $1.20 million, showing the business can still generate positive gross margin before overhead.
The company held $1.35 million in cash and equivalents at quarter-end.
Long-term debt fell to $781 thousand, down from $589 thousand in Q3 2025? Actually the quarter-to-quarter debt mix looks volatile, but long-term borrowings remained relatively modest versus total liabilities.
Depreciation and amortization remain manageable non-cash expenses, and capital spending was light at only $26.8 thousand in Q1 2026.
The company reported cash interest paid of $212 thousand, indicating debt service remains a real cash use.
Q1 2026 net loss was $2.60 million, or -$0.05 per share, so the company is still far from consistent profitability.
Operating cash flow was negative $2.45 million, which means the core business is still burning cash.
Financing cash flow was also negative $1.34 million, including debt repayment and other financing outflows, leading to a $3.92 million decline in cash.
Total current liabilities of $11.79 million exceeded current assets of $4.84 million, suggesting weak near-term liquidity.

Trend analysis over the last several years

Revenue has been volatile but generally improved from the 2023 level. Quarterly revenue moved from about $1.45 million in Q3 2023 to $3.16 million in Q1 2026, with several quarters in the $3.0 million to $4.0 million range. That is a constructive sign for top-line demand.

However, expense structure has been inconsistent and often heavy. Gross profit improved in multiple periods, but operating expenses frequently outpaced gross profit. For example, in Q1 2026 operating expenses were $4.17 million versus gross profit of $1.20 million, producing an operating loss of $2.97 million.

The most concerning historical period was Q3 2024, when the company recorded a massive impairment charge of $56.7 million and net loss of $53.9 million. While that looks like a one-time hit rather than a recurring quarterly run rate, it highlights the risk of asset write-downs and business-model volatility.

Cash flow has also been uneven. In some quarters the company generated positive financing inflows to offset operating losses, but the most recent quarter showed the opposite: operating losses were funded less by financing and more by the balance sheet, resulting in a sharp cash decline. That pattern is not ideal for investors looking for self-funding growth.

Balance sheet takeaways

At the end of Q1 2026, VSee Health reported total assets of $19.0 million and total liabilities of $12.7 million, leaving common equity of about $6.3 million. That is better than the negative equity position seen in some earlier quarters, but the company still carries a heavy liability load relative to assets.

Working capital remains a concern. Current liabilities were well above current assets, and accounts payable plus short-term debt made up a large portion of the liability structure. On the asset side, a sizable portion of the balance sheet is tied up in goodwill and intangible assets, which are less flexible than cash.

Bottom line

VSee Health is showing signs of commercial activity and revenue generation, but the company is not yet demonstrating durable profitability or strong cash generation. Investors should focus on whether revenue can keep growing while operating expenses stabilize. Until then, the stock likely remains a high-risk turnaround story rather than a fundamentally secure operating business.

07/20/26 08:58 PM ETAI Generated. May Contain Errors.

Digital Health Acquisition Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Digital Health Acquisition's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Digital Health Acquisition's net income appears to be on an upward trend, with a most recent value of -$14.71 million in 2025, rising from -$3.24 million in 2022. The previous period was -$57.70 million in 2024.

Digital Health Acquisition's total operating income in 2025 was -$9.58 million, based on the following breakdown:

Total Gross Profit: $7.36 million
Total Operating Expenses: $16.94 million

Over the last 3 years, Digital Health Acquisition's total revenue changed from $0.00 in 2022 to $14.62 million in 2025, a change of 1,461,818,400.0%.

Digital Health Acquisition's total liabilities were at $16.96 million at the end of 2025, a 15.2% decrease from 2024, and a 272.4% increase since 2021.

In the past 4 years, Digital Health Acquisition's cash and equivalents has ranged from $107.00 thousand in 2022 to $5.27 million in 2025, and is currently $5.27 million as of their latest financial filing in 2025.

Over the last 3 years, Digital Health Acquisition's book value per share changed from -1.80 in 2022 to 0.27 in 2025, a change of -115.0%.

Related Companies

Financial statements for NASDAQ:DHAC last updated on 7/18/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Digital Health Acquisition (DHAC) Financials

Financials Breakdown Chart

Key Financial Trends

Digital Health Acquisition Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Digital Health Acquisition (DHAC) Financials

Annual Income Statements for Digital Health Acquisition

Quarterly Income Statements for Digital Health Acquisition

Annual Cash Flow Statements for Digital Health Acquisition

Quarterly Cash Flow Statements for Digital Health Acquisition

Annual Balance Sheets for Digital Health Acquisition

Quarterly Balance Sheets for Digital Health Acquisition

Annual Metrics And Ratios for Digital Health Acquisition

Quarterly Metrics And Ratios for Digital Health Acquisition

Financials Breakdown Chart

Key Financial Trends

Digital Health Acquisition Financials - Frequently Asked Questions

When does Digital Health Acquisition's financial year end?

How has Digital Health Acquisition's net income changed over the last 3 years?

What is Digital Health Acquisition's operating income?

How has Digital Health Acquisition's revenue changed over the last 3 years?

How much debt does Digital Health Acquisition have?

How much cash does Digital Health Acquisition have?

How has Digital Health Acquisition's book value per share changed over the last 3 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools